Neuren Media and Analyst Coverage, page-1076

I really appreciate the effort made by some but I am in line with TonyWAIW, I would like to have a DCF model (like the one done on Neuren) done on the Acadia pipeline from 3/4 years ago (I say Acadia because we all know it ) when it had Nuplazid already approved and in the running on various very important pathologies, trofinetide in phase 3 and other preclinical studies in various partnerships (PW was not there) and with the stock quoted between $45 and $60, in this hypothetical study done let's say in 2020 how much could we expect after 4 years (so now)? Would it have been right for shareholders to accept a takeover at $70/80 in 2020? Since I am a simple shareholder of Neuren, I blindly trust the management otherwise I would have already sold, so whatever the hypothetical sales figure for Neuren is it will be well accepted, and $50 is over 4B USD not peanuts.